Blog

  • European Markets Retreat as Gulf Conflict Intensifies: DAX, CAC, FTSE100

    European Markets Retreat as Gulf Conflict Intensifies: DAX, CAC, FTSE100

    European equities opened lower on Thursday as renewed military tensions in the Gulf raised concerns over the stability of the fragile ceasefire between the United States and Iran, while also clouding prospects for a broader diplomatic agreement between the two countries.

    At 07:02 GMT, the pan-European Stoxx 600 index had declined 0.4%. Germany’s DAX fell 0.5%, France’s CAC 40 slipped 0.4%, and the FTSE 100 in London dropped 0.7%.

    Fresh Military Strikes Renew Investor Concerns

    Investor sentiment weakened after reports that the U.S. military launched additional strikes inside Iran on Wednesday, following Iranian drone attacks targeting commercial vessels in the Strait of Hormuz.

    According to the Wall Street Journal, citing officials familiar with the matter, U.S. forces destroyed a drone and targeted a drone-control facility near the southern Iranian port city of Bandar Abbas.

    Iran’s Islamic Revolutionary Guard Corps later stated that it had retaliated by striking a U.S. military base and warned that any future attacks would trigger further responses.

    Diplomatic Efforts Continue Without Breakthrough

    Despite the latest escalation, diplomatic discussions aimed at ending the conflict continued, although negotiators failed to secure an immediate breakthrough in talks surrounding the nearly three-month-long crisis.

    Elsewhere in the region, Kuwait’s military reported intercepting incoming missiles and drones, ending what had previously been a relatively calm period lasting several weeks without direct attacks.

    Oil Prices Climb on Supply Concerns

    Energy markets reacted to the growing instability, with Brent crude futures rising 2.6% to $96.72 per barrel.

    Although oil prices remained below the symbolic $100-per-barrel level, they continue to trade significantly above levels seen before the conflict began.

  • FTSE 100 Falls as Renewed U.S.-Iran Attacks Undermine Ceasefire Optimism

    FTSE 100 Falls as Renewed U.S.-Iran Attacks Undermine Ceasefire Optimism

    British equities moved lower on Thursday, tracking declines across European markets after a renewed exchange of military strikes between the United States and Iran weakened hopes for a diplomatic breakthrough in the Middle East. Investor sentiment was also pressured by warnings from the European Central Bank that energy-driven inflation risks may remain elevated for longer than markets currently expect.

    By 07:26 GMT, the FTSE 100 had dropped 0.92%, while Germany’s DAX declined 0.34% and France’s CAC 40 slipped 0.41%. Sterling also weakened slightly, falling 0.18% against the U.S. dollar to $1.3402.

    Fresh Military Escalation Raises Regional Tensions

    Market anxiety intensified after the U.S. military confirmed it had carried out new defensive strikes near Bandar Abbas on Wednesday. According to U.S. officials, the operation targeted a ground control station believed to be preparing drone launches against commercial and military vessels operating in the Strait of Hormuz.

    Iran’s Revolutionary Guards responded early Thursday, claiming they had struck the U.S. air base used to launch the attack. Kuwait later reported that its air defence systems had intercepted missiles and drones, marking one of the most direct exchanges between the two sides in recent days.

    Diplomatic Progress Overshadowed by Conflict

    The latest military escalation overshadowed earlier signs that diplomatic efforts might be gaining traction.

    Speaking during a Cabinet meeting, U.S. President Donald Trump said Iran was “negotiating on fumes,” while adding, “maybe we have to go back and finish it, maybe we don’t.”

    Secretary of State Marco Rubio also indicated there had been “progress and interest” toward a possible agreement, stressing that diplomacy remained Washington’s preferred course of action.

    Meanwhile, the White House dismissed Iranian state television reports claiming that a draft “Islamabad Framework” agreement existed under which Tehran would oversee shipping transit through the Strait of Hormuz, describing the report as “a complete fabrication.”

    Tehran Maintains Hard-Line Position

    Further uncertainty emerged from comments made by senior Iranian officials.

    Iran’s Supreme National Security Council stated that the country’s enriched uranium stockpile remained outside the scope of negotiations, while a senior Iranian lawmaker warned that even a U.S. agreement “would not mean the end of the war.”

    Deputy foreign minister Ali Bagheri Kani also reiterated demands that all frozen Iranian assets be returned “fully and unconditionally,” a condition that President Trump has already rejected.

    ECB Warns Energy Inflation Could Persist

    Adding to investor concerns, ECB chief economist Philip Lane warned on Thursday that the energy shock linked to Middle East tensions could continue affecting inflation even if the conflict is resolved relatively quickly.

    Speaking at a conference hosted by the Bank of Japan and its affiliated think tank in Tokyo, Lane cautioned about potential “second-round effects” as countries seek to rebuild energy reserves and diversify supply chains.

    Financial markets are currently pricing in two additional ECB interest rate hikes, while expectations for a third increase remain roughly balanced.

  • Market Open: SSE Infrastructure Spending, Johnson Matthey Cash Flow

    Market Open: SSE Infrastructure Spending, Johnson Matthey Cash Flow

    FTSE 100 falls as Gulf tensions lift Brent crude, while SSE boosts infrastructure investment and Johnson Matthey beats cash flow estimates.

    Market Overview

    European markets traded lower amid renewed geopolitical tensions in the Gulf region after reports of fresh US-Iran strike exchanges weakened hopes of a ceasefire. The FTSE 100 fell 0.80 per cent to 10,406.44, while the DAX slipped 0.03 per cent and the S&P 500 lost 0.31 per cent. The Nasdaq also moved lower as investors monitored escalating tensions alongside concerns over energy supply disruption and broader global growth risks.

    Commodity markets reflected the heightened uncertainty, with Brent crude climbing above $94 per barrel on fears surrounding the Strait of Hormuz and supply flows. Gold remained supported by demand for defensive assets, while Bitcoin weakened against sterling as broader risk appetite softened. Sterling traded weaker against most major currencies, with investors also assessing the outlook for inflation and central bank policy amid rising energy prices.


    Market Numbers

    FTSE 100: Down (-0.80%), 10,406.44
    CAC40: Up (0.43%), 8,207.890
    DAX: Down (-0.03%), 25,177.80
    NASDAQ: Down (-0.36%), 29,880.0
    S&P 500: Down (-0.31%), 7,515.0


    In the Headlines

    Infrastructure Expansion – SSE (LSE:SSE)
    SSE accelerated infrastructure spending plans to support long-term growth tied to the energy transition, with investment focused on electricity networks and renewable energy projects. The move highlights continued demand for grid upgrades and clean energy infrastructure across the UK.

    Cash Flow Growth – Johnson Matthey (LSE:JMAT)
    Johnson Matthey reported that FY26 free cash flow more than doubled and exceeded analyst expectations, supported by operational improvements and stronger business performance. The update may strengthen investor confidence in the company’s restructuring and capital allocation strategy.


    Currencies (vs GBP)

    USD: Down (-0.13%), $1.3402
    CHF: Down (-0.10%), Fr.1.05594
    EUR: Down (-0.04%), €1.1538
    JPY: Down (-0.20%), ¥213.782
    AUD: Up (0.16%), $1.881840
    Bitcoin (BTC/GBP): Down (-1.49%), £54,578.6


    Commodities

    Copper: Down (0.35%), 6.34338
    Gold: Down (1.42%), 4,392.96
    Brent Crude: Up (2.35%), 94.61
    Natural Gas: Down (-0.26%), 3.072

  • SkinBioTherapeutics Finalises Financial Investigation and Appoints New Auditor Ahead of Results Publication (SBTX)

    SkinBioTherapeutics Finalises Financial Investigation and Appoints New Auditor Ahead of Results Publication (SBTX)

    SkinBioTherapeutics (LSE:SBTX) said its board has completed an investigation into the company’s financial statements for the year ended 30 June 2025 and is preparing to publish its delayed interim HY26 results together with restated, unaudited FY25 accounts.

    The company noted that trading in its shares, which remains suspended, is expected to resume once the outstanding financial information and related remedial measures have been released. Publication has taken longer than initially anticipated, extending beyond the original end-May timetable due to challenges encountered while gathering supporting evidence during the review process.

    New Auditor Appointed Following Tender Process

    Alongside the update, SkinBioTherapeutics confirmed the appointment of Saffrey LLP as its new independent auditor for the financial year ending 30 June 2026. The appointment follows a formal competitive tender exercise conducted by the board.

    Outgoing auditor Gravita Audit II Limited stated that there were no matters requiring attention from shareholders or creditors in connection with its departure. The company said this confirmation should help support efforts to rebuild investor confidence in its financial reporting standards and corporate governance procedures.

    Governance Improvements Follow Period of Uncertainty

    Management is aiming to restore stability following the accounting review and share suspension, with the upcoming publication of revised results expected to provide greater clarity on the company’s financial position and future direction.

    The company’s outlook is held back primarily by ongoing unprofitability and weak cash flows, despite strong revenue growth and a relatively conservative balance sheet. Technicals also remain bearish with the stock trading below major moving averages and negative MACD, while valuation is constrained by losses (negative P/E) and no dividend yield support.

    More about SkinBioTherapeutics

    SkinBioTherapeutics is a UK-based life science company focused on skin health, built around its proprietary SkinBiotix platform developed with the University of Manchester. Its core business targets the skin healthcare market across five pillars, led by cosmetic skincare via partner Croda’s Zenakine-branded actives and AxisBiotix food supplements for inflammatory skin conditions, sold online, on Amazon and through selected Superdrug stores.

    The group is also pursuing a consolidator strategy, acquiring complementary skincare and cosmetic businesses that add distribution reach, geographic presence and manufacturing capability to support its in-house product pillars. SkinBioTherapeutics has been listed on London’s AIM market since April 2017 and is headquartered in Newcastle, positioning it within the UK’s specialist life sciences and dermatology ecosystem.

  • IQE Strengthens Balance Sheet With £81 Million Fundraise as AI Photonics Demand Expands (IQE)

    IQE Strengthens Balance Sheet With £81 Million Fundraise as AI Photonics Demand Expands (IQE)

    IQE (LSE:IQE) reported full-year 2025 revenue of £97.3 million, representing a decline of 17.6% compared with the previous year, as weaker smartphone demand and wider macroeconomic uncertainty weighed on its wireless division. In contrast, photonics revenue increased 15%, driven by stronger demand from defence applications and AI-focused data-centre infrastructure.

    Adjusted EBITDA declined to £3.2 million during the period, although the company improved operating cash flow and reduced capital expenditure as part of ongoing efficiency measures. IQE also continued investing in gallium nitride (GaN) and microLED production capabilities while further optimising its global manufacturing operations.

    Strategic Investment Reshapes Financial Position

    A recently completed £81 million fundraising has significantly strengthened the company’s balance sheet. The financing included a £45 million strategic investment alongside long-term supply agreements with MACOM.

    Following completion of the transaction, IQE repaid its revolving credit facility and reported net cash inflows of £27.9 million, improving financial flexibility and liquidity.

    Management said the strengthened balance sheet will support future growth initiatives while allowing the business to capitalise on increasing demand across high-growth semiconductor markets.

    AI and Data-Centre Demand Drives 2026 Momentum

    The company reported strong trading momentum entering 2026, with accelerating demand for indium phosphide (InP) photonics products used in AI infrastructure and data-centre applications. IQE also highlighted solid order activity from aerospace, defence and smartphone customers.

    Based on current trading conditions, management expects revenue growth of more than 20% in 2026 and anticipates a return to high single-digit to low double-digit EBITDA margins as operational leverage improves.

    Financial Challenges Still Influence Valuation

    The company’s outlook is held down primarily by weak financial performance (negative profitability and deteriorating cash flow) and a loss-making valuation profile (negative P/E). This is partially offset by strong recent technical momentum, with the price trading above key moving averages and positive MACD.

    More about IQE plc

    IQE plc, based in Cardiff, is a leading global supplier of compound semiconductor wafer products and advanced material solutions. The group focuses on photonics, wireless, power and display applications, serving fast-growing markets such as AI-driven data centres, aerospace and defence, consumer smartphones, automotive sensing and emerging microLED displays.

  • Petro Matad Moves Closer to PetroChina Sales Agreement While Expanding Renewable Energy Ambitions (MATD)

    Petro Matad Moves Closer to PetroChina Sales Agreement While Expanding Renewable Energy Ambitions (MATD)

    Petro Matad (LSE:MATD) said approval of its 2026 Oil Sales Agreement with PetroChina is expected shortly, paving the way for the sale of approximately 35,000 barrels of accumulated oil production from Block XX. The company expects the agreement to allow sales at current higher market prices, potentially improving near-term cash generation.

    Production from the Heron-1 and Gazelle-1 wells continues to perform in line with or above company expectations. Management also noted that operating costs have remained under control despite increased production volumes across the field operations.

    Alongside ongoing production activity, Petro Matad is evaluating a potential near-term 3D seismic survey programme aimed at improving reservoir understanding and supporting future appraisal and development drilling plans.

    Partner Discussions and Renewable Expansion Continue

    The company said farm-out negotiations relating to Block XX and Block VII have progressed more slowly than initially anticipated. However, stronger oil prices have recently generated renewed interest from prospective partners, widening Petro Matad’s strategic options.

    Beyond hydrocarbons, the group is continuing to expand its renewable energy business through SunSteppe Renewable Energy. The division is advancing plans for a 200MW hybrid power project and is also participating in tenders or early-stage discussions for several additional solar, wind and battery storage developments ranging between 90MW and 100MW.

    Management believes these projects position the company to benefit from Mongolia’s growing demand for renewable and grid-stabilising energy infrastructure as the country accelerates its energy transition strategy.

    Operational Updates and Shareholder Engagement

    Petro Matad also confirmed arrangements for its upcoming Annual General Meeting in Ulaanbaatar, with shareholders able to participate either in person or remotely. The company said further updates are expected as the PetroChina sales agreement progresses, seismic plans advance and renewable project opportunities develop further.

    Financial Outlook Remains Mixed

    The company’s outlook is held back primarily by very weak profitability and consistently negative (and worsening) free cash flow, despite sharp revenue growth. A strong, low-debt balance sheet provides an important offset, while technical signals are mixed/neutral and valuation remains challenging due to losses and lack of dividend data.

    More about Petro Matad

    Petro Matad Limited is an AIM-quoted oil and gas company focused on exploration and production in Mongolia, primarily through its Block XX and Block VII licences. The group also has a growing presence in renewable energy via its SunSteppe Renewable Energy arm, which is developing large-scale hybrid wind, solar and battery storage projects to support Mongolia’s power grid and energy transition.

  • OptiBiotix Improves Revenue and Margins as Focus Shifts Toward Sustainable Profitability (OPTI)

    OptiBiotix Improves Revenue and Margins as Focus Shifts Toward Sustainable Profitability (OPTI)

    OptiBiotix Health (LSE:OPTI) reported strong financial progress for 2025, with revenue increasing 34% to £1.17 million and gross profit climbing 85% to £614,000. Gross margins also improved significantly to 53%, supported by continued expansion in international markets, particularly across Asia, which now contributes 73% of total group revenue.

    The company ended the year with cash reserves of £1.04 million and no debt, while its listed shareholdings in ProBiotix Health and SkinBioTherapeutics were valued at approximately £6.45 million. OptiBiotix also carried forward an additional £212,000 of customer orders into the 2026 financial year.

    International Expansion and Product Development Drive Momentum

    Operationally, the business continued expanding the commercial reach of its SlimBiome weight-management ingredient, including its launch within the Hydroxycut brand in the United States. The company also secured a new distribution agreement with a major direct-selling weight management company and reported rapid growth across Asian markets, where 17 products have now launched.

    OptiBiotix additionally introduced an upgraded enzyme-based production process for SweetBiotix, designed to improve manufacturing yields, reduce costs and enhance taste performance. Alongside this, its WellBiome platform is being evaluated in a hospital-led clinical study examining potential reductions in intensive care stays and healthcare costs.

    Record Order Intake Supports 2026 Outlook

    The company entered 2026 with strong commercial momentum, reporting record order intake early in the year. This included a 24-tonne SlimBiome order in Taiwan and total January orders exceeding £800,000.

    Management said its strategic priorities are now evolving from rapid expansion toward achieving commercial sustainability and improved profitability. Planned measures include annual cost reductions of between £500,000 and £600,000, lower SlimBiome production expenses and the introduction of dedicated business-unit profit and loss accountability by the end of 2026.

    Financial Challenges Still Influence Outlook

    The company’s outlook is weighed down primarily by persistent losses and cash burn despite strong 2024 revenue growth, and by weak technicals showing a sustained downtrend with negative momentum. A debt-free balance sheet provides some support, but valuation remains difficult to justify with negative earnings and no dividend yield provided.

    More about OptiBiotix Health

    OptiBiotix Health is a UK-listed life sciences company focused on microbiome-based ingredients and products designed to reduce hunger and food cravings, improve gut health and offer sweet fibre sugar substitutes. Its core portfolio includes prebiotic brands such as SlimBiome, WellBiome, SweetBiotix and Microbiome Modulators, complemented by interests in skincare and probiotics via stakes in SkinBioTherapeutics and ProBiotix Health.

  • Defence Holdings Launches Strategic Operating Model and Expands Into Autonomous Defence Systems (ALRT)

    Defence Holdings Launches Strategic Operating Model and Expands Into Autonomous Defence Systems (ALRT)

    Defence Holdings (LSE:ALRT) has introduced a formal Operating Model designed to connect defence customer requirements with emerging technologies and private capital investment. The company said the framework is intended to create a scalable platform capable of identifying, developing and commercialising strategic digital defence capabilities.

    Management believes the model positions the group to capitalise on evolving trends within the European defence sector, where demand is increasing for sovereign, software-defined and AI-enabled systems alongside faster innovation cycles and enhanced defence readiness.

    OM Defence Partnership Marks First Strategic Deal

    As part of the new strategy, Defence Holdings has completed its first strategic partnership agreement through an investment in OM Defence Systems, a company specialising in autonomous and counter-UAS technologies.

    The arrangement includes both a revenue-linked interest and an equity position in OM Defence, whose sovereign manufacturing ambitions have been shaped by operational experience gained in Ukraine and across Europe. Defence Holdings said the partnership offers multiple potential routes for long-term value creation while strengthening its exposure to rapidly expanding defence segments such as drone warfare and counter-drone systems.

    The company also confirmed that its at-the-market share issuance programme has now generated cumulative proceeds of £877,967.49, providing additional funding to support strategic development initiatives. The programme has also resulted in a modest reduction in the ownership position of one major shareholder.

    Strategic Momentum Offset by Financial Pressures

    The company’s outlook reflects significant financial challenges, with negative equity and cash flow issues being the most critical factors. While technical analysis indicates bearish momentum, recent corporate events provide a positive outlook, suggesting potential strategic improvements. The lack of traditional valuation metrics adds uncertainty to the stock’s market valuation.

    More about Defence Holdings

    Defence Holdings PLC is a UK-based, software-led defence technology company and the country’s first listed business of its kind. Its five-year strategy targets sovereign digital capabilities for national security, resilience and defence readiness, with a focus on software-defined and AI-enabled systems for European defence customers.

  • Touchstone Exploration Increases Trinidad Production and Targets Improved Gas Pricing (TXP)

    Touchstone Exploration Increases Trinidad Production and Targets Improved Gas Pricing (TXP)

    Touchstone Exploration (LSE:TXP) has increased oil production from its WD-8 block in Trinidad following the successful start-up of the FR-1835 and FR-1836 development wells during mid-May. The two wells are currently producing a combined 175 barrels per day of medium crude oil, providing an immediate boost to production and operating cash flow.

    The development activity was financed through a previously completed asset swap transaction, allowing the company to expand production while maintaining a disciplined capital allocation approach.

    Cascadura Upgrades and Gas Strategy Advance

    Alongside the new oil production, Touchstone is progressing infrastructure improvements at its Cascadura gas facility, including the installation of a booster compressor designed to improve operational efficiency and reduce bottlenecks within the system.

    The company is also preparing a stimulation programme at the Carapal Ridge 3 well as part of wider efforts to optimise gas output and accelerate reserve monetisation.

    Management said the business is expected to benefit from stronger gas pricing in the near term as gas volumes from the Central block are redirected during maintenance work affecting Atlantic LNG operations. The temporary market conditions are anticipated to improve gas realizations and support stronger revenue generation.

    Operational Improvements Support Growth Strategy

    Touchstone said its current operational focus remains centred on high-return investment opportunities and improving production reliability across its Trinidad portfolio. By enhancing infrastructure at Cascadura and taking advantage of shifting gas market dynamics during the Train 4 maintenance outage, the company aims to strengthen its financial performance and competitive position among Caribbean-focused exploration and production operators.

    More about Touchstone Exploration

    Touchstone Exploration Inc. is a Calgary-based oil and gas company focused on acquiring, exploring, developing and producing petroleum and natural gas assets. The group operates exclusively onshore in Trinidad and Tobago, with its shares listed on the Toronto Stock Exchange and London Stock Exchange under the symbol TXP, giving it access to both North American and U.K. capital markets.

  • Nuformix Advances Inhaled Fibrosis Therapy Following Orphan Drug Milestones and New Funding Support (NFX)

    Nuformix Advances Inhaled Fibrosis Therapy Following Orphan Drug Milestones and New Funding Support (NFX)

    Nuformix (LSE:NFX) reported interim results showing continued progress for NXP002, its lead inhaled treatment candidate targeting idiopathic pulmonary fibrosis (IPF) and other progressive fibrosing interstitial lung diseases. The company recently secured U.S. FDA Orphan Drug Designation for the enabled form of tranilast used within the programme, adding to the European Medicines Agency orphan designation already granted for the therapy.

    Management said the dual orphan status is helping to strengthen ongoing discussions with potential partners regarding licensing or broader collaboration opportunities. Preclinical studies have also continued to demonstrate strong anti-fibrotic and anti-inflammatory activity from NXP002, both as a standalone treatment and when used alongside existing standard-of-care therapies.

    Improved Financial Position Supports Development Strategy

    Nuformix reported a reduced half-year loss of £346,577, while loss per share improved to 0.02p. The company’s financial position was supported by a heavily oversubscribed open offer followed by a separate £1 million share subscription.

    As a result, cash and cash equivalents increased to £930,283, while net assets rose to £1.64 million. The company said the newly raised funds are being directed toward generating additional value-enhancing data for NXP002 and refining the programme in line with feedback from prospective commercial partners.

    Management believes this strategy could improve the prospects of securing an out-licensing agreement and help advance the programme toward clinical development in what is expected to become a rapidly expanding IPF treatment market.

    Financial Constraints Continue to Weigh on Outlook

    The company’s outlook is primarily constrained by weak financial performance (no recent revenue, ongoing losses, and persistent cash burn), partially offset by a low-debt balance sheet. Technicals are modestly negative with the price below key moving averages, and valuation provides limited support due to a negative P/E and no dividend yield data.

    More about Nuformix Plc

    Nuformix plc is a UK-based pharmaceutical development company focused on targeting unmet medical needs in fibrosis and oncology through drug repurposing. It leverages expertise in discovering and patenting novel forms of existing drugs with improved physical properties, aiming to create differentiated products in terms of dose, delivery route or presentation and to secure early-stage licensing opportunities from its preclinical pipeline. Nuformix shares trade on the Main Market of the London Stock Exchange under the ticker NFX, giving the company access to public capital to fund development of assets such as its lead inhaled therapy NXP002 for fibrotic lung diseases.